Abstract:The pleotropic nature of interleukin-2 (IL2) has allowed it to be used as both a pro-inflammatory and anti-inflammatory therapeutic agent, through promotion of regulatory T cell (Treg) responses via the IL2RA receptor or promotion of CD8 T cell responses via the IL2RB receptor, respectively. However, the utility of IL2 as a treatment is limited by this same pleiotropy, and protein engineering to bias specificity towards either the regulatory T cell (Treg) or CD8 T cell lineage often requires a trade-off in protein production or total bioactivity. Here we use SolubiS, a computational algorithm-based method, to predict mutations within the IL2 structure to improve protein production yield while altering cellular selectivity, to generate a mutein with elevated therapeutic potential. The design and testing process identified the V126R (murine) / V111R (human) mutation as a Treg-enhancing mutein, creating a cation repulsion to inhibit primary binding to IL2RB, with a post-IL2RA confirmational shift enabling secondary IL2RB binding, and hence allowing the trimeric receptor complex to form. In human IL2, additional N110R T151R aggregation-protecting mutations could improve protein yield of the V111R mutation. The approach also generated novel CD8 T cell-promoting mutations. Y79K created a cation-cation repulsion with IL2RA, while Q50W enhanced CD8 T cell activity through potential π-stacking enhancing binding to IL2RB, with the combination highly stimulatory for CD8 T cells. For human IL2, Y65K (homolog to murine Y79K) coupled with E82K prevented IL2RA binding, however it required the aggregation-protecting mutations of N110R T151R to rescue production. These muteins, designed with both cellular specificity and protein production features, have potential as both biological tools and therapeutics.

De novo design of mini-binder proteins against IL-2 receptor β chain

Directed disruption of IL2 aggregation sites produces designer biologics with enhanced specificity coupled to improved production capacity

Insights into the binding recognition and computational design of IL-2 muteins with enhanced predicted binding affinity to the IL-2 receptor α

De novo design of a protein binder against Staphylococcus enterotoxin B

Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides

Regulating IL-2 immune signaling function via a core allosteric structural network

Study of the Molecular Mechanism of Interleukin-2 Mutein D10 Binding to IL-2 Receptors by Molecular Simulations

New Therapeutic Strategies Based on Biasing IL-2 Mutants for Cancers and Autoimmune Diseases.

De novo design of protein minibinder agonists of TLR3

Interleukin-2 druggability is modulated by global conformational transitions controlled by a helical capping switch

De novo design of highly selective miniprotein inhibitors of integrins αvβ6 and αvβ8

Design of cell-type-specific hyperstable IL-4 mimetics via modular de novo scaffolds

Design of High Affinity Binders to Convex Protein Target Sites

De novo design of miniprotein antagonists of cytokine storm inducers

The design of antagonist peptide of hIL-6 based on the binding epitope of hIL-6 by computer-aided molecular modeling.

New Therapeutic Strategies Based on IL-2 to Modulate Treg Cells for Autoimmune Diseases

Discovery of Potent and Highly Selective Interleukin-2-Inducible T-Cell Kinase Degraders with in Vivo Activity.

Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist

Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes

Proximity-enabled Covalent Binding of IL-2 to IL-2Rα Selectively Activates Regulatory T Cells and Suppresses Autoimmunity.